ANTIMICROBIAL RESISTANCE: A GLOBAL CRISIS

Pilar Ramon-Pardo

Special Program on Antimicrobial Resistance

Departament of Communicable Diseases and Environmental Determinants of Health



From the laboratory to the international arena


GLOCAL ACTION PLAN






PAHO/WHO


Huge Variation on the Burden of Infectious Diseases by country and by age group







Antimicrobial resistance: economic impact





- The costs could be as serious as those of the 2008 financial crisis.
- It reduces GDP substantially, but, unlike the crisis, the impact may last longer and affect more low-income countries.

World Bank Group Report on Drug-Resistant Infections (March 2017)

AMR and SDGs



AMR strikes hardest on the poor


- → Rate of resistance is high
- → Lack affordable treatment



Antibiotic residues from hospitals, pharmaceutical companies and agriculture contaminate the water



Untreatable infections in animals threaten sustainable food production for our population



*Cumulative costs of AMR is predicted to be US \$120 trillion by 2050





It is crucial to balance access, innovation and conservation of antimicrobials to contain AMR



All of which require multi-stakeholder partnerships

> *World Bank Group Report on Drug-Resistant Infections (March 2017)

THE ONE HEALTH COLLABORATION







World leader in food & agriculture

World leader in animal health & welfare


World leader in human health

Tripartite Agreement / Collaboration
(Common priorities including antimicrobial resistance)

Global Action Plan's 5 Strategic Objectives


- 1. Improve awareness and understanding
- 2. Strengthen knowledge through surveillance & research
- 3. Reduce the incidence of infection
- 4. Optimize the use of antimicrobial medicines
- 5. Ensure sustainable investment


Develop National Action Plan
Bring AMR to the <u>UNGA</u>



PAHO/WHO

MONITORING OF COUNTRY PROGRESS ON AMR (2018)





Source: http://www.who.int/antimicrobial-resistance/global-action-plan/database/en/





CARBAPENEM NON-SUSCEPTIBLE KLEBSIELLA PNEUMONIAE


Latin America, 2000-2017













Average % non-susceptibility





5%-<10%

10%-<25%

Data Under Review*

■ No Data Reported

Data Source: ReLAVRA



Our time with **ANTIBIOTICS** is running out.

Antibiotics are in danger of losing their effectiveness due to misuse and overuse, and in many cases they aren't even needed.

Always seek the advice of a healthcare professional before taking antibiotics.

ANTIBIOTICS STITH CASE



CONCLUSION: MULTI-SECTORAL APPROACH NEEDED

- Raise awareness economic and societal costs: investments needed
- Political engagement and high-level coordination of multi-sectoral activities against AMR needed
- Ensure public & private investment in new medicines, diagnostic tools & vaccines while ensuring access to these measures is equitable and affordable
- Encourage the engagement of stakeholders from their countries, including civil society, academic and research institutions, the public and policy makers



Misuse of ANTIBIOTICS puts us all at risk.

Taking antibiotics when you don't need them speeds up antibiotic resistance. Antibiotic resistant infections are more complex and harder to treat. They can affect anyone, of any age, in any country.

Always seek the advice of a healthcare professional before taking antibiotics.





PAN AMERICAN **JOURNAL OF** PUBLIC HEALTH

CALL FOR PAPERS



ANTIMICROBIAL RESISTANCE

Deadline: September 30, 2019

More info: www.paho.org/journal



